Technical Analysis for MCRB - Seres Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 25.36 -0.43% -0.11
MCRB closed down 3.85 percent on Wednesday, September 23, 2020, on 14 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical MCRB trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish -0.43%
Bollinger Band Squeeze Range Contraction -0.43%
20 DMA Support Bullish -4.27%
Bollinger Band Squeeze Range Contraction -4.27%
20 DMA Support Bullish -3.46%
Bollinger Band Squeeze Range Contraction -3.46%
20 DMA Support Bullish -1.13%
Hammer Candlestick Bullish -1.13%
1,2,3 Pullback Bullish Bullish Swing Setup -1.13%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.13%
Older End-of-Day Gignals for MCRB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 4 hours ago
Rose Above 20 DMA about 4 hours ago
Up 1% about 4 hours ago
20 DMA Resistance about 7 hours ago
Down 3% about 7 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Seres Therapeutics, Inc., a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed open label Phase Ib/2 clinical study for the prevention of further recurrences of Clostridium difficile infection (CDI). The company's product candidates in pre-clinical development comprise SER-262, an Ecobiotic microbiome therapeutic designed to be used following antibiotic treatment of primary CDI to prevent the initial recurrence of CDI; SER-287 to treat inflammatory bowel disease, including ulcerative colitis; and SER-155 to treat enteric pathogens, such as antibiotic-resistant bacteria. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Medicine Autoimmune Diseases Inflammatory Bowel Disease Ulcerative Colitis Diarrhea Antimicrobial Resistance Digestive Diseases Clostridioides Difficile Clostridium Difficile Infection

Is MCRB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 33.0
52 Week Low 2.52
Average Volume 3,508,944
200-Day Moving Average 7.39
50-Day Moving Average 17.66
20-Day Moving Average 25.51
10-Day Moving Average 26.25
Average True Range 1.93
ADX 41.85
+DI 28.94
-DI 18.11
Chandelier Exit (Long, 3 ATRs ) 22.53
Chandelier Exit (Short, 3 ATRs ) 27.97
Upper Bollinger Band 27.81
Lower Bollinger Band 23.21
Percent B (%b) 0.49
BandWidth 18.01
MACD Line 2.03
MACD Signal Line 2.58
MACD Histogram -0.553
Fundamentals Value
Market Cap 1.03 Billion
Num Shares 40.5 Million
EPS -2.42
Price-to-Earnings (P/E) Ratio -10.52
Price-to-Sales 17.96
Price-to-Book 4.50
PEG Ratio 0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.59
Resistance 3 (R3) 27.70 27.09 27.24
Resistance 2 (R2) 27.09 26.55 27.04 27.12
Resistance 1 (R1) 26.28 26.22 25.98 26.18 27.00
Pivot Point 25.68 25.68 25.53 25.63 25.68
Support 1 (S1) 24.87 25.14 24.57 24.76 23.94
Support 2 (S2) 24.26 24.80 24.21 23.82
Support 3 (S3) 23.45 24.26 23.70
Support 4 (S4) 23.35